From new product introductions to swiped trade secrets, chipmakers have stolen the spotlight so far this week. But let’s not forget about biotech stocks, five of which are highlighted in IBD’s Screen of the Day, Big Cap Leaders, along with their semiconductor counterparts. The large-cap biotechs include Celgene (CELG), Regeneron Pharmaceuticals (REGN) and Gilead Sciences (GILD) Celgene, which has a highest-possible IBD Composite Rating of 99,
Manny Rivelo, incoming chief executive of F5 Networks, has a tough act to follow, but he has brought a new way of thinking at the company. Under John McAdam, F5’s CEO since 2000, the company grew to $1.7 billion in 2014 revenue, up from $100 million when he took the reins. McAdam is retiring June 30, but will stay on as board chairman. Seattle-based F5 Networks (FFIV) is the No. 1 seller of application delivery controllers, which direct data
Chinese security software and Internet search giant Qihoo 360 Technology (QIHU) beat Wall Street expectations for Q1 earnings and revenue late Tuesday. Qihoo posted Q1 earnings ex items of 57 cents a share, up nearly 6% year over year. Wall Street had expected a decline to 49 cents amid heavy spending. Sales rose 45% year over year to $384.4 million, slowing for the fourth straight quarter. But Q1 marked the 10th straight quarter of double-digit